Gastrin-releasing peptide as a molecular target for inflammatory diseases: an update

Inflamm Allergy Drug Targets. 2013 Jun;12(3):172-7. doi: 10.2174/1871528111312030003.

Abstract

Gastrin-releasing peptide (GRP) is a neuropeptide that acts through G protein coupled receptors and is involved in signal transmission in both the central and peripheral nervous systems. Its receptor, gastrin-releasing peptide receptor (GRPR), is expressed by various cell types, and it is overexpressed in cancer cells. In recent years, studies have suggested the relationship of GRP and inflammatory diseases. RC-3095, a selective GRPR antagonist, was found to have antiinflammatory properties in models of arthritis, gastritis, uveitis and sepsis. Furthermore, GRP mediates air pollutioninduced airway hyperreactivity and airway inflammation in mice. In conclusion, GRP and its receptor are relevant to the inflammatory response, being a potential therapeutic target several diseases are related to inflammation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Air Pollution / adverse effects
  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Bombesin / analogs & derivatives*
  • Bombesin / pharmacology
  • Bombesin / therapeutic use
  • Disease Models, Animal
  • Gastrin-Releasing Peptide / antagonists & inhibitors*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Mice
  • Molecular Targeted Therapy
  • Neuroimmunomodulation
  • Peptide Fragments / pharmacology*
  • Peptide Fragments / therapeutic use
  • Receptors, Bombesin / genetics
  • Receptors, Bombesin / metabolism*
  • Respiratory Hypersensitivity / drug therapy
  • Respiratory Hypersensitivity / etiology
  • Respiratory Hypersensitivity / metabolism*
  • Signal Transduction / drug effects

Substances

  • Anti-Inflammatory Agents
  • Peptide Fragments
  • Receptors, Bombesin
  • bombesin (6-14), Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-
  • Gastrin-Releasing Peptide
  • Bombesin